BRPI0407501A - glicolipìdeos e método sintético dos mesmos bem como seus intermediários sintéticos, e método sintético dos mesmos - Google Patents

glicolipìdeos e método sintético dos mesmos bem como seus intermediários sintéticos, e método sintético dos mesmos

Info

Publication number
BRPI0407501A
BRPI0407501A BRPI0407501-3A BRPI0407501A BRPI0407501A BR PI0407501 A BRPI0407501 A BR PI0407501A BR PI0407501 A BRPI0407501 A BR PI0407501A BR PI0407501 A BRPI0407501 A BR PI0407501A
Authority
BR
Brazil
Prior art keywords
substituted
unsubstituted
group
synthetic
synthetic method
Prior art date
Application number
BRPI0407501-3A
Other languages
English (en)
Inventor
Hirokazu Annoura
Kenji Murata
Takashi Yamamura
Original Assignee
Daiichi Suntory Pharma Co Ltd
Japan President Nat Ct Neurology & Psychiatry
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Suntory Pharma Co Ltd, Japan President Nat Ct Neurology & Psychiatry filed Critical Daiichi Suntory Pharma Co Ltd
Publication of BRPI0407501A publication Critical patent/BRPI0407501A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C247/00—Compounds containing azido groups
    • C07C247/02—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C247/04—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)

Abstract

"GLICOLIPìDEOS E MéTODO SINTéTICO DOS MESMOS BEM COMO SEUS INTERMEDIáRIOS SINTéTICOS, E MéTODO SINTéTICO DOS MESMOS". Novos derivados glicolipídicos, onde o substituinte da parte da base de esfingosina é um grupamento alquil de cadeia de carbono curta, um grupamento cicloalquil substituído ou não substituído, um grupamento aril substituído ou não substituído ou um grupamento aralquil substituído ou não substituído e métodos sintéticos eficientes para produção em massa realizável dos mesmos e intermediários úteis para a síntese destes compostos. São sintetizados quimicamente glicolipídeos tendo a fórmula (I): onde R¬ 3¬ indica um grupamento alquil linear C~ 1~ a C~ 7~ substituído ou não substituído, um grupamento cicloalquil substituído ou não substituído, um grupamento aril substituído ou não substituído, ou um grupamento aralquil substituído ou não substituído e R¬ 3¬ indica um grupamento alquil C~ 1~ a C~ 35~ substituído ou não substituído, um grupamento aril substituído ou não substituído ou um grupamento aralquil substituído ou não substituído.
BRPI0407501-3A 2003-02-14 2004-02-13 glicolipìdeos e método sintético dos mesmos bem como seus intermediários sintéticos, e método sintético dos mesmos BRPI0407501A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003037397 2003-02-14
PCT/JP2004/001566 WO2004072091A1 (ja) 2003-02-14 2004-02-13 糖脂質誘導体及びその製造法並びにそれらの合成中間体及びその製造法

Publications (1)

Publication Number Publication Date
BRPI0407501A true BRPI0407501A (pt) 2006-02-14

Family

ID=32866358

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0407501-3A BRPI0407501A (pt) 2003-02-14 2004-02-13 glicolipìdeos e método sintético dos mesmos bem como seus intermediários sintéticos, e método sintético dos mesmos

Country Status (12)

Country Link
US (2) US7732583B2 (pt)
EP (2) EP1619199B1 (pt)
JP (2) JP4742220B2 (pt)
KR (1) KR20050105215A (pt)
CN (2) CN101165047B (pt)
AU (1) AU2004210784A1 (pt)
BR (1) BRPI0407501A (pt)
CA (1) CA2515396A1 (pt)
ES (2) ES2676345T3 (pt)
HU (1) HUE037560T2 (pt)
NO (1) NO20054032L (pt)
WO (1) WO2004072091A1 (pt)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9809654B2 (en) 2002-09-27 2017-11-07 Vaccinex, Inc. Targeted CD1d molecules
EP1784196B1 (en) * 2004-08-27 2016-12-21 Albert Einstein College Of Medicine Of Yeshiva University Ceramide derivatives as modulators of immunity and autoimmunity
US7923013B2 (en) * 2004-12-28 2011-04-12 The Rockefeller University Glycolipids and analogues thereof as antigens for NKT cells
US7534434B2 (en) 2004-12-28 2009-05-19 The Rockefeller University Glycolipids and analogues thereof as antigens for NK T cells
CA2613350A1 (en) * 2005-07-01 2007-01-11 Japan As Represented By President Of National Center Of Neurology And Ps Ychiatry Glycolipid derivative and drug containing the same as active component
WO2008047174A1 (en) 2006-10-18 2008-04-24 Centre National De La Recherche Scientifique Alpha-galactosylceramide analogs, their methods of manufacture, intermediate compounds useful in these methods, and pharmaceutical compositions containing them
AU2008219020B2 (en) * 2007-02-21 2013-08-22 Vaccinex, Inc. Modulation of NKT cell activity with antigen-loaded CDId molecules
CN102325875B (zh) 2009-01-08 2018-04-10 阿尔伯爱因斯坦医学有限公司 具有细胞壁结合神经酰胺类糖脂的细菌疫苗及其应用
CN101775051B (zh) * 2010-01-07 2013-03-27 北京大学 一种区域选择性脱除糖o-苄基保护基的方法
US10632740B2 (en) 2010-04-23 2020-04-28 Landa Corporation Ltd. Digital printing process
US10190012B2 (en) 2012-03-05 2019-01-29 Landa Corporation Ltd. Treatment of release layer and inkjet ink formulations
US10434761B2 (en) 2012-03-05 2019-10-08 Landa Corporation Ltd. Digital printing process
CN104271687B (zh) 2012-03-05 2016-11-02 兰达公司 油墨膜构造
US9902147B2 (en) 2012-03-05 2018-02-27 Landa Corporation Ltd. Digital printing system
US9498946B2 (en) 2012-03-05 2016-11-22 Landa Corporation Ltd. Apparatus and method for control or monitoring of a printing system
US10642198B2 (en) 2012-03-05 2020-05-05 Landa Corporation Ltd. Intermediate transfer members for use with indirect printing systems and protonatable intermediate transfer members for use with indirect printing systems
EP2822776B1 (en) 2012-03-05 2018-08-01 Landa Corporation Ltd. Transfer printing method
US9643403B2 (en) 2012-03-05 2017-05-09 Landa Corporation Ltd. Printing system
EP2823006B1 (en) 2012-03-05 2020-09-30 Landa Corporation Ltd. Ink film constructions
WO2013132418A2 (en) 2012-03-05 2013-09-12 Landa Corporation Limited Digital printing process
CN109177531B (zh) 2012-03-15 2020-11-27 兰达公司 打印系统的环形柔性皮带
AU2014214770B2 (en) 2013-02-08 2018-09-06 Albert Einstein College Of Medicine Inc. Modified glycolipids and methods of making and using the same
US9371352B2 (en) 2013-02-08 2016-06-21 Vaccinex, Inc. Modified glycolipids and methods of making and using the same
GB201401173D0 (en) 2013-09-11 2014-03-12 Landa Corp Ltd Ink formulations and film constructions thereof
US9782993B2 (en) 2013-09-11 2017-10-10 Landa Corporation Ltd. Release layer treatment formulations
GB2536489B (en) 2015-03-20 2018-08-29 Landa Corporation Ltd Indirect printing system
GB2537813A (en) 2015-04-14 2016-11-02 Landa Corp Ltd Apparatus for threading an intermediate transfer member of a printing system
DE112017002714T5 (de) 2016-05-30 2019-02-28 Landa Corporation Ltd. Digitales Druckverfahren
GB201609463D0 (en) 2016-05-30 2016-07-13 Landa Labs 2012 Ltd Method of manufacturing a multi-layer article
WO2019077489A1 (en) 2017-10-19 2019-04-25 Landa Corporation Ltd. FLEXIBLE BELT WITHOUT END FOR A PRINTING SYSTEM
JP7225230B2 (ja) 2017-11-19 2023-02-20 ランダ コーポレイション リミテッド デジタル印刷システム
WO2019102297A1 (en) 2017-11-27 2019-05-31 Landa Corporation Ltd. Digital printing system
US11707943B2 (en) 2017-12-06 2023-07-25 Landa Corporation Ltd. Method and apparatus for digital printing
US11679615B2 (en) 2017-12-07 2023-06-20 Landa Corporation Ltd. Digital printing process and method
WO2020003088A1 (en) 2018-06-26 2020-01-02 Landa Corporation Ltd. An intermediate transfer member for a digital printing system
US10994528B1 (en) 2018-08-02 2021-05-04 Landa Corporation Ltd. Digital printing system with flexible intermediate transfer member
US12001902B2 (en) 2018-08-13 2024-06-04 Landa Corporation Ltd. Correcting distortions in digital printing by implanting dummy pixels in a digital image
JP7246496B2 (ja) 2018-10-08 2023-03-27 ランダ コーポレイション リミテッド 印刷システムおよび方法に関する摩擦低減手段
WO2020136517A1 (en) 2018-12-24 2020-07-02 Landa Corporation Ltd. A digital printing system
EP3946953A4 (en) 2019-03-31 2022-12-14 Landa Corporation Ltd. SYSTEMS AND METHODS FOR PREVENTING OR MINIMIZING PRINT DEFECTS IN PRINTING PROCESSES
CN114746813A (zh) 2019-11-25 2022-07-12 兰达公司 在数字印刷中使用红外辐射来干燥油墨
US11321028B2 (en) 2019-12-11 2022-05-03 Landa Corporation Ltd. Correcting registration errors in digital printing
EP4081866A4 (en) 2019-12-29 2024-01-03 Landa Corporation Ltd. PRINTING METHOD AND SYSTEM
JP7714237B2 (ja) * 2020-11-12 2025-07-29 国立研究開発法人理化学研究所 擬似糖脂質誘導体並びにその合成中間体、製造方法及び用途
EP4264377A4 (en) 2021-02-02 2024-11-13 Landa Corporation Ltd. MITIGATION OF DISTORTIONS IN PRINTED IMAGES
EP4301374A4 (en) 2021-03-01 2025-09-10 Deciduous Therapeutics Inc COMPOUNDS FOR ACTIVATING INVARIANT NATURAL KILLER T CELLS AND METHODS OF USE IN ELIMINATING INFLAMMATORY SENESCENT CELLS
WO2025033387A1 (ja) * 2023-08-07 2025-02-13 Ｅａファーマ株式会社 糖脂質誘導体の製造法及びそれらの合成中間体並びにその結晶体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6072960A (ja) * 1983-09-30 1985-04-25 Sumitomo Chem Co Ltd モノアゾ化合物およびそれを用いて染色または捺染する方法
JPH0559081A (ja) 1991-08-29 1993-03-09 Kirin Brewery Co Ltd 新規スフインゴ糖脂質、その製造法および使用
US5936076A (en) * 1991-08-29 1999-08-10 Kirin Beer Kabushiki Kaisha αgalactosylceramide derivatives
AU683026B2 (en) * 1992-10-22 1997-10-30 Kirin Pharma Kabushiki Kaisha Novel shingoglycolipid and use thereof
JP2002226377A (ja) * 1996-10-14 2002-08-14 Kirin Brewery Co Ltd 配糖体含有末梢血幹細胞増加剤
JP3495740B2 (ja) * 1997-04-10 2004-02-09 麒麟麦酒株式会社 α−グリコシルセラミドを含有するＮＫＴ細胞活性化剤
EP1437358B1 (en) * 2001-08-16 2006-10-18 Daiichi Asubio Pharma Co., Ltd. Novel glycolipid and remedial agent for autoimmune disease containing the same as active ingredient

Also Published As

Publication number Publication date
EP1619199B1 (en) 2013-12-18
AU2004210784A1 (en) 2004-08-26
CN1768072A (zh) 2006-05-03
EP1619199A1 (en) 2006-01-25
CN101165047B (zh) 2010-10-20
NO20054032D0 (no) 2005-08-30
CN101165047A (zh) 2008-04-23
CA2515396A1 (en) 2004-08-26
US20060074235A1 (en) 2006-04-06
EP2343306A1 (en) 2011-07-13
JP5246448B2 (ja) 2013-07-24
ES2450043T3 (es) 2014-03-21
US8034908B2 (en) 2011-10-11
US7732583B2 (en) 2010-06-08
JPWO2004072091A1 (ja) 2006-06-01
JP2011063593A (ja) 2011-03-31
ES2676345T3 (es) 2018-07-18
KR20050105215A (ko) 2005-11-03
EP1619199A4 (en) 2009-12-16
JP4742220B2 (ja) 2011-08-10
HUE037560T2 (hu) 2018-09-28
NO20054032L (no) 2005-11-01
US20100210828A1 (en) 2010-08-19
EP2343306B1 (en) 2018-04-04
WO2004072091B1 (ja) 2004-11-11
CN100537585C (zh) 2009-09-09
WO2004072091A1 (ja) 2004-08-26

Similar Documents

Publication Publication Date Title
BRPI0407501A (pt) glicolipìdeos e método sintético dos mesmos bem como seus intermediários sintéticos, e método sintético dos mesmos
ATE302001T1 (de) Stabilisierte askorbinsäurederivate
BR0206433A (pt) Composto, composição farmacêutica, processo para a prepapação de um composto, e, uso de um composto
BR0317703A (pt) Composto, formulação farmacêutica, uso de um composto, processo para a preparação de compostos, e, intermediários
BR9908764A (pt) Composto e seus sais farmaceuticamente aceitáveis ou ésteres hidrolisáveis in vivo, uso destes, processo para prepará-los, e, composição farmacêutica
BRPI0613403A2 (pt) tetrahidrobenzodiazepinas aril- e heteroarila-substituÍdas e uso das mesmas para bloquear a recaptaÇço de norepinefrina, dopamina e serotonina
HRP20020926B1 (en) Arylmethylamine derivatives for use as tryptase inhibitors
TNSN05007A1 (en) Novel thiophenylglycoside derivatives, methods for production thereof, medicaments comprising said compounds and use thereof.
CY1111843T1 (el) 2-υποκατεστημενα αναλογα βιταμινης d και θεραπευτικες χρησεις αυτων
EA200200098A1 (ru) Ароматические сложные эфиры для маркировки или мечения нефтепродуктов
EP1634874A4 (en) imidazolidine
EA200401053A1 (ru) Оксо-азабициклические соединения
DK1706414T3 (da) Fremgangsmåde til fluorcytidinderivater
DK1022276T3 (da) Epoxysuccinamidderivater
PT1265891E (pt) Novos derivados heterociclicos ou benzenicos do acido lipoico sua preparacao e sua aplicacao a titulo de medicamentos
TR200001239T2 (tr) Tiyazolidinediyon türevlerini hazırlama prosesi.
BRPI0518958B8 (pt) método para produzir um derivado de biopterina, 1;2'-0- diacetil-l-biopterina e l-biopterina
EP1535920A4 (en) PROCESS FOR PREPARING 1,3-BENZODIOXOL-2-SPIRO-CYCLOALKANE DERIVATIVES
WO2003082840A1 (fr) Agoniste du récepteur k-opioïde comprenant un dérivé de 2-phénylbenzothiazoline
BRPI9710537B8 (pt) derivados da eritromicina, composições farmacêuticas, bem como processo para preparação dos mesmos.
ATE419373T1 (de) Anthelmintische substanz fki-1033 und verfahren zur herstellung davon
BRPI0406955A (pt) Composto de bisoxazolina opticamente ativos, processo para a sua produção e seu uso
DE60335960D1 (de) 1,2,4-triazolderivat, verfahren zu dessenherstellung, und dieses enthaltende pharmazeutische zusammensetzung
BRPI0412253A (pt) derivados de nicotinamida úteis como inibidores de pde4
BRPI0413057A (pt) processo para preparação de imipenem

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.

B15K Others concerning applications: alteration of classification

Ipc: C07D 317/28 (2006.01), C07C 247/04 (2006.01), C07H